Avedro, Inc. announced that it has been granted approval from the South Korean Ministry of Food and Drug Safety (MFDS, formerly the KFDA) for the company's KXL Cross-Linking System. The KXL System components include the VibeX family of riboflavin formulations. The KXL device is designed to perform Lasik Xtra and accelerated cross-linking for keratoconus and post-LASIK ectasia.

Lasik Xtra is a three minute procedure performed in conjunction with standard LASIK to restore biomechanical integrity and strength to the cornea after a LASIK procedure. The procedure combines riboflavin ophthalmic solution with UVA irradiation from Avedro's KXL device to achieve accelerated corneal cross-linking. For keratoconus and ectasia patients, accelerated cross-linking has the ability to halt progression of the condition in its early phases.